Here's the dividend forecast out to 2030 for Sigma shares

This business could pay healthy dividends in the coming years…

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points
  • Sigma Healthcare Ltd, owner of Chemist Warehouse, is projected to deliver long-term dividend growth, starting with a forecasted dividend of 4 cents per share in FY26, according to UBS.
  • UBS predicts Sigma's market share and sales will grow due to strategic advantages and expansion, with Chemist Warehouse leading the charge in Australia's health and beauty market.
  • By FY30, dividends could reach 8 cents per share, potentially doubling from FY26, driven by continued sales growth, profit margin improvements, and market expansion.

Owning Sigma Healthcare Ltd (ASX: SIG) shares could be a pleasing choice for long-term dividend income.

It may not have a reputation for being an ASX dividend share year, but if it's able to deliver year after year growth, then it could build a reputation for reliability.

There's no guarantee of how dividend payments are going to play out, but analysts are optimistic that the owner of the Chemist Warehouse, Amcal and Discount Drug Store brands could perform for investors. It has a presence in Australia and New Zealand, as well as countries including Ireland and the UAE.

Stethoscope with a piggy bank and hundred dollar notes.

Image source: Getty Images

FY26

The 2026 financial year is Sigma Healthcare's current financial year, so it's the most relevant for investors to know.

According to the forecast from the broker UBS, the owner of Chemist Warehouse is predicted to deliver an annual dividend per share of 4 cents.

UBS says that Chemist Warehouse, the key driver of Sigma Healthcare, is the leader in the attractive health and beauty market, which is growing at 6% per year, according to UBS' estimates.

Pleasingly, the broker expects Sigma Healthcare to continue gaining market share in the coming years. Due to leadership in price and range, regulatory advantages, compliance and its ability to fulfil online and in-store orders.

The sales growth, with both like-for-like (LFL) sales and store network expansion going well, is delivering operating leverage.

Chemist Warehouse LFL sales growth is expected by UBS to increase to 13.2% to in FY26. Its store count is forecast to grow at 33 per year because of franchisor support, acquisitions and international growth in existing and possibly new markets.

Combined with gross profit growth and the realisation of synergies after the merger, the company's sales should support operating profit (EBIT) margin growth, according to UBS. The broker predicts the EBIT margin can grow from 10.1% in FY26 and rise each year to 11.6% in FY30.

With all of that in mind, UBS predicts that owners of Sigma shares could receive an annual dividend per share of 4 cents in FY26.

FY27

Chemist Warehouse sales are expected to see LFL growth of 10.2% in FY27 and then high single digit growth through to the end of the decade thanks to an ageing population, health prioritisation, higher value medicines and greater category participation and spending per consumer in health and beauty.

This could help drive the company's annual dividend per share to 5 cents in FY27.

FY28

Sales, margins and profit could continue to rise in the 2028 financial year. This could help deliver a rise in the company's dividend per share to 6 cents.

FY29

The good times are predicted to continue into the 2029 financial year, giving the business even more economic firepower to increase the payout.

In FY29, UBS predicts the business could hike its payout again to 7 cents per share.

FY30

The final year of this series of projections could see the business decide to declare a dividend per share of 8 cents. If these forecasts prove correct, it would mean the dividend doubles between FY26 and FY30.

Motley Fool contributor Tristan Harrison has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

ASX share investor sitting with a laptop on a desk, pondering something.
Share Fallers

CSL shares crash to a 9-year low. Is it time to sell off my shares?

What's next for the beaten-down ASX biotech stock?

Read more »

Six smiling health workers pose for a selfie.
Healthcare Shares

This ASX biotech hit a 90% success rate. Can it unlock commercial growth?

Orthocell is already seeing growing adoption, with more than 300 surgeons across over 220 hospitals in Australia using Remplir.

Read more »

Researchers and doctors with futuristic 3D hologram overlay for body anatomy or DNA in hospital clinic.
Healthcare Shares

This ASX biotech is pushing for a Nasdaq listing. Could it reignite investor interest?

The NASDAQ has a reputation for providing a platform for some of the world's most innovative companies.

Read more »

Smiling health care workers in a medical setting.
Healthcare Shares

3 ASX healthcare shares to buy amid sector rout: experts

Healthcare shares have tumbled 36% over the past year amid multiple headwinds for the sector.

Read more »

Person pressing the buy button on a smartphone.
Broker Notes

3 reasons to buy Pro Medicus shares today

A leading analyst believes Pro Medicus shares are now trading at a significant discount.

Read more »

Medical workers examine an x-ray or scan in a hospital laboratory.
Healthcare Shares

This ASX biotech has just announced a major US deal

This company's heart disease technology is gaining traction.

Read more »

Devastated woman sits near smartphone on home kitchen floor troubled with loneliness.
Healthcare Shares

Which beaten down ASX healthcare stock is a better buy right now: Pro Medicus vs Cochlear shares

Which do experts prefer?

Read more »

Health professional working on his laptop.
Healthcare Shares

Already up 42% this year, Morgans says this ASX healthcare stock can continue to rocket

This broker sees big upside for this healthcare stock.

Read more »